CompletedNCT00373672
Safety study of armodafinil (Nuvigil) in schizophrenia
It tested armodafinil (Nuvigil) for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Nashville, United StatesSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
Study information
Study start dateAugust 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 58
- Sponsor
- Northwestern University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00373672
- Official title
- Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder
Recruitment & locations
CompletedNashville
Questions about this study
Who is behind this study?
The study sponsor is Northwestern University, a university.
Did this study involve medication?
Yes. The study involved medication, including armodafinil (Nuvigil) and placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedNCT06880328
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in people with Schizophrenia
This study is completed in the United States. It focuses on schizophrenia.
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.